HYPERTENSION BURDEN AND PREDICTORS AMONG ADULTS RECEIVING SYSTEMIC CANCER THERAPY: A REAL-WORLD SINGLE-CENTER COHORT STUDY
Author(s)
Hadeel Alkofide1, Lamya Alnaim, Doctorate2, GHADAH BAWAZEER, Doctorate2.
1Riyadh, Saudi Arabia, 2King saud University, Riyadh, Saudi Arabia.
1Riyadh, Saudi Arabia, 2King saud University, Riyadh, Saudi Arabia.
OBJECTIVES: Hypertension (HTN) is a common cardiovascular complication during systemic cancer therapy and may increase blood pressure (BP) monitoring and antihypertensive treatment needs. We estimated the burden of treatment-period HTN and identified associated factors.
METHODS: We conducted a retrospective cohort study of 648 adults diagnosed with cancer between 2015 and 2022 at a tertiary hospital in Riyadh, Saudi Arabia, following institutional review board approval. We assessed BP at baseline and at 3, 6, and 12 months after therapy initiation. We defined HTN as confirmed elevated BP on repeated readings. Treatment-period HTN was assessed in the full cohort, while newly detected HTN was assessed among patients without a documented HTN history. Multivariable logistic regression identified factors independently associated with HTN, reporting adjusted odds ratios (ORs) with 95% confidence intervals (CIs). Analyses used R version 4.6.0.
RESULTS: Mean age was 60.4 years (standard deviation [SD] 14.1), 51.5% were female, and mean body mass index (BMI) was 28.3 kg/m2. Overall, 67.7% had treatment-period HTN (439/648). Among 426 patients without a documented HTN history, 61.5% had newly detected HTN (262/426). After adjustment for baseline BP status, treatment-period HTN was associated with monoclonal antibody therapy (OR 2.72; 1.35-5.90), male sex (OR 1.71; 1.15-2.55), higher BMI (OR 1.06 per kg/m2; 1.02-1.09), and older age (OR 1.02 per year; 1.00-1.03). For newly detected HTN, associated factors were male sex (OR 2.47; 1.57-3.91), higher BMI (OR 1.08; 1.04-1.12), older age (OR 1.02; 1.00-1.04), and monoclonal antibody therapy (OR 2.36; 1.02-5.97).
CONCLUSIONS: Newly detected hypertension was common among patients with cancer within a year of starting treatment. Risk was higher in men, older patients, and those with higher BMI or receiving monoclonal antibody therapy. Monitoring blood pressure during treatment, with prompt management, may help prevent complications and reduce hypertension burden in this population. Prospective studies are needed to confirm these findings.
METHODS: We conducted a retrospective cohort study of 648 adults diagnosed with cancer between 2015 and 2022 at a tertiary hospital in Riyadh, Saudi Arabia, following institutional review board approval. We assessed BP at baseline and at 3, 6, and 12 months after therapy initiation. We defined HTN as confirmed elevated BP on repeated readings. Treatment-period HTN was assessed in the full cohort, while newly detected HTN was assessed among patients without a documented HTN history. Multivariable logistic regression identified factors independently associated with HTN, reporting adjusted odds ratios (ORs) with 95% confidence intervals (CIs). Analyses used R version 4.6.0.
RESULTS: Mean age was 60.4 years (standard deviation [SD] 14.1), 51.5% were female, and mean body mass index (BMI) was 28.3 kg/m2. Overall, 67.7% had treatment-period HTN (439/648). Among 426 patients without a documented HTN history, 61.5% had newly detected HTN (262/426). After adjustment for baseline BP status, treatment-period HTN was associated with monoclonal antibody therapy (OR 2.72; 1.35-5.90), male sex (OR 1.71; 1.15-2.55), higher BMI (OR 1.06 per kg/m2; 1.02-1.09), and older age (OR 1.02 per year; 1.00-1.03). For newly detected HTN, associated factors were male sex (OR 2.47; 1.57-3.91), higher BMI (OR 1.08; 1.04-1.12), older age (OR 1.02; 1.00-1.04), and monoclonal antibody therapy (OR 2.36; 1.02-5.97).
CONCLUSIONS: Newly detected hypertension was common among patients with cancer within a year of starting treatment. Risk was higher in men, older patients, and those with higher BMI or receiving monoclonal antibody therapy. Monitoring blood pressure during treatment, with prompt management, may help prevent complications and reduce hypertension burden in this population. Prospective studies are needed to confirm these findings.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
CO5
Topic
Clinical Outcomes, Epidemiology & Public Health, Study Approaches
Topic Subcategory
Relating Intermediate to Long-term Outcomes
Disease
Cardiovascular Disorders (including MI, Stroke, Circulatory), Oncology